Recce Pharmaceuticals advances anti-infective programs, expands funding

Recce Pharmaceuticals Ltd announced a net loss of A$21,428,089 for the fiscal year ended June 30, 2025, an increase from A$17,661,714 in 2024, primarily due to increased R&D expenditure. Despite this, the company made significant strides in its clinical programs, securing approval from Indonesia's Badan POM to initiate a Registrational Phase 3 clinical trial for RECCE® 327 Topical Gel (R327G) in diabetic foot infections (DFIs). This was followed by Human Research Ethics Committee (HREC) approval for the same trial in Indonesia and for expanding its Phase II ABSSSI clinical trial to include up to 20 additional DFI patients.

Positive data from the Phase II ABSSSI trial showed 93% primary efficacy endpoint at 14 days and 86% clinical response at 7 days with R327G. Commercially, Recce successfully raised A$15.8m in capital and secured a debt facility of up to ~$30m, with $11.5m drawn. The company also received a $2m grant from the U.S. Department of Defense for R327G in burn wound infections and a Canadian SR&ED Tax Incentive rebate of $175,122.

The company's intellectual property expanded with patent grants for Anti-infectives in Australia (expiry 2037), Japan (expiry 2041), and China (expiry 2041). Preclinical studies yielded promising efficacy data for R327 against multidrug-resistant Acinetobacter baumannii and Mycobacterium abscessus, reinforcing its broad-spectrum potential.